#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Oral semaglutide dropout rates in Japan
A Japanese database study found that high HbA1c and concurrent metformin use predicted early discontinuation of oral semaglutide at the 3 mg starting dose.
"Ozempic Face" Prevention: A New Risk Model
A 2026 paper proposes an anatomy-driven risk model and four-phase prevention algorithm for GLP-1-associated facial aging.
Semaglutide at 6 months: STEP trial data
Community posts report 80-90 lbs lost in six months on semaglutide. Here is what STEP trial data shows about timelines and plateaus.
Semaglutide and beta-cell function in T1D
A 2026 case study reports preserved beta-cell function and stable blood sugar in a newly diagnosed type 1 diabetes patient treated with semaglutide.
Semaglutide cut fentanyl seeking in rats
A 2026 rat study found that single doses of semaglutide prevented cue-, drug- and stress-triggered fentanyl seeking. Human trials are next.
Semaglutide and Alzheimer's: EVOKE review
A new paper revisits the EVOKE trials and finds limited semaglutide signals at later timepoints, despite the primary endpoint failure at two years.
Semaglutide weight loss: the trial data
STEP 5 shows 15% average weight loss sustained at two years. What the data says about body composition, eating behaviour, and stopping.
Semaglutide resolves MASLD inflammation
A 2026 meta-analysis of 10 trials found semaglutide resolved steatohepatitis and cut liver fat in MASLD patients, but fibrosis improvement was not significant.
Semaglutide and menstrual changes
Semaglutide users report heavier periods and cycle shifts. Here is what safety data and clinical research say about GLP-1 agonists and menstruation.
Semaglutide eased RLS in Parkinson's case
A 2026 case report found that semaglutide improved treatment-resistant restless legs syndrome in one Parkinson's disease patient. The finding is preliminary.
Semaglutide below max dose: real-world data
A Slovak observational study found 11.35% mean weight loss at six months on submaximal semaglutide doses. Below trial figures, but clinically relevant.
Most statin label warnings lack evidence
A 2026 Lancet meta-analysis found only 4 of 66 listed statin side effects are backed by trial evidence. What GLP-1 users should know.